Andrew Green Sells 11,480 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Andrew Green sold 11,480 shares of Artivion stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $24.97, for a total transaction of $286,655.60. Following the completion of the transaction, the senior vice president owned 40,160 shares in the company, valued at approximately $1,002,795.20. This represents a 22.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Artivion Price Performance

Shares of AORT opened at $25.13 on Friday. Artivion, Inc. has a fifty-two week low of $19.16 and a fifty-two week high of $48.25. The company has a market capitalization of $1.23 billion, a price-to-earnings ratio of -358.92 and a beta of 1.25. The firm has a 50-day simple moving average of $26.27 and a 200-day simple moving average of $28.78. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter. The firm had revenue of $125.76 million for the quarter, compared to analysts’ expectations of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. On average, equities research analysts anticipate that Artivion, Inc. will post 0.45 earnings per share for the current year.

Institutional Investors Weigh In On Artivion

A number of hedge funds and other institutional investors have recently bought and sold shares of AORT. BlackRock Inc. acquired a new stake in shares of Artivion in the second quarter valued at about $149,965,000. Conestoga Capital Advisors LLC purchased a new stake in Artivion during the first quarter worth about $43,044,000. California State Teachers Retirement System grew its position in Artivion by 2,086.7% during the second quarter. California State Teachers Retirement System now owns 1,119,860 shares of the company’s stock worth $25,163,000 after buying an additional 1,068,647 shares during the period. Summit Partners Public Asset Management LLC purchased a new position in Artivion in the fourth quarter valued at about $39,401,000. Finally, Invesco Ltd. increased its holdings in Artivion by 211.9% in the fourth quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock valued at $50,228,000 after buying an additional 748,119 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on AORT shares. Weiss Ratings cut Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Wall Street Zen lowered shares of Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Citigroup reissued a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Canaccord Genuity Group upped their price objective on shares of Artivion from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Finally, Stifel Nicolaus set a $45.00 target price on shares of Artivion in a research note on Monday, June 1st. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $44.83.

About Artivion

Artivion, Inc is a medical device company focused on developing and supplying products used in cardiac and vascular surgery. The company’s portfolio includes implantable devices, surgical products and preservation technologies designed to treat diseases of the heart and aorta.

Its products include the On-X mechanical heart valve, aortic stent grafts and surgical grafts, as well as BioGlue Surgical Adhesive and other products used to control bleeding and reinforce tissue during cardiovascular procedures.